Rheumatoid arthritis (disorder)
PEAC: Pathobiology of Early Arthritis Cohort
Year Started: 2008
Prospective, observational study in patients with early symptomatic inflammatory arthritis (http://www.peac-mrc.mds.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at two timepoints - Baseline & Follow-up (6 month), please note figures for baseline samples are represented (6 month sample availability on request). Demographic & clinical data is available & collected at 5 timepoints over a 1-year follow-up period (Baseline, 3, 6, 9 & 12 months). Current recruitment status for Rheumatoid Arthritis cohort is 214 patients (1st April 2019).
- Access:
- Closed to access
- Type:
- Cohort
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | 0 - 3 months |
Clinical records | 0 - 3 months |
Followup records | 0 - 3 months |
Freezer temperature logs | 0 - 3 months |
Genomic datasets | 0 - 3 months |
Imaging data | 0 - 3 months |
Pathology records | 0 - 3 months |
Physiological/biochemical measurements | 0 - 3 months |
Quality indicators | 0 - 3 months |
Treatment records | 0 - 3 months |
Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
RNA | -60°C to -85°C | N/A | Affected | 51 - 75% | |
Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
Urine | -60°C to -85°C | N/A | Affected | 75% -99% |
Rheumatoid arthritis (disorder)
R4-RA: A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA
Year Started: 2013
Open-label, randomised controlled clinical trial, multi-centre, multi-country, Phase IV study (http://www.r4ra-nihr.whri.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at multiple timepoints (details available on request), please note figures for baseline samples are represented (availability of samples from other timepoints on request). Demographic & clinical data is available & collected at multiple timepoints over a 2-year follow-up period. Recruitment status for this study is 164 patients.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | 0 - 3 months |
Clinical records | 0 - 3 months |
Followup records | 0 - 3 months |
Freezer temperature logs | 0 - 3 months |
Genomic datasets | 0 - 3 months |
Imaging data | 0 - 3 months |
Pathology records | 0 - 3 months |
Quality indicators | 0 - 3 months |
Treatment records | 0 - 3 months |
Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
RNA | -60°C to -85°C | N/A | Affected | 75% -99% | |
Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
Rheumatoid arthritis (disorder)
STRAP: Stratification of Biologic Therapies for RA by Pathobiology. A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab.
Year Started: 2015
Open-label, randomised controlled clinical trial, multi-centre, multi-country, Phase III study (http://www.matura-mrc.whri.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at multiple timepoints (details available on request), please note figures for baseline samples are represented (availability of samples from other timepoints on request). Demographic & clinical data is available & collected at multiple timepoints over a 2-year follow-up period. Current recruitment status for this study is 200 patients (1st April 2019).
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | 0 - 3 months |
Clinical records | 0 - 3 months |
Followup records | 0 - 3 months |
Freezer temperature logs | 0 - 3 months |
Genomic datasets | 0 - 3 months |
Imaging data | 0 - 3 months |
Pathology records | 0 - 3 months |
Physiological/biochemical measurements | 0 - 3 months |
Quality indicators | 0 - 3 months |
Treatment records | 0 - 3 months |
Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
RNA | -60°C to -85°C | N/A | Affected | 75% -99% | |
Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
Systemic lupus erythematosus (disorder)
BHSLE: Sequencing Based Genetic Analysis of Systemic Lupus Erythematosus (SLE)
Year Started: 2015
DNA and clinical information are used to look for similarities and differences between people with SLE and those unaffected by the disease. These data can be used to identify genetic differences that are more common in SLE patients and then ask how these genetic factors affect the immune system and how they influence the nature and severity of the disease. Current recruitment status for this study is 220 patients.
- Access:
- Closed to access
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 3 - 6 months |
Freezer temperature logs | 0 - 3 months |
Donor Ethnicity | 3 - 6 months |
Unknown
Data not recorded
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
DNA | -60°C to -85°C | N/A | Affected | 75% -99% | |
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 51 - 75% | |
Plasma | -60°C to -85°C | N/A | Affected | 75% -99% |